As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international equity markets are not just keeping pace with their American counterparts but are decisively outperforming them. While
Eli Lilly (NYSE: LLY) launches Employer Connect platform on March 5, 2026, offering Zepbound tirzepatide KwikPen at $449 across all doses to expand employer-sponsored obesity coverage.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Bristol-Myers Squibb (NYSE:BMY) and its peers.
As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the boardroom have returned with a vengeance. Leading investment banks, including Morgan Stanley (NYSE: MS), are now projecting a staggering
NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a precarious regulatory and legal bind. As of March 4, 2026, the company finds itself at a crossroads, battling
As the first quarter of 2026 unfolds, the equity markets are at a historic crossroads. Morgan Stanley (NYSE:MS) has stunned Wall Street with a revised year-end target for the S&P 500, projecting the index will reach 7,800—a bold 14% gain from current levels. This bullish stance
The final trading week of February 2026 has laid bare a striking fracture in the U.S. equity markets. While the technology sector continues to feast on a relentless AI-driven "execution" cycle, the broader market indices are increasingly weighed down by deep-seated structural issues in the healthcare and industrial sectors.
In a dramatic departure from his historically cautious stance, Mike Wilson, Chief U.S. Equity Strategist at Morgan Stanley (NYSE: MS), has stunned Wall Street by raising the firm’s 12-month S&P 500 price target to a lofty 7,800. This projection, released as the market moves through the
As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional "Big Pharma" mainstay, Lilly has transcended its industry peers to become a high-octane growth engine, recently flirting
In a defining moment for global financial markets, the S&P 500 Index officially breached the 7,000-point mark for the first time in history on January 28, 2026. This monumental achievement underscores a multi-year bull run that has defied skeptics, survived geopolitical volatility, and transitioned from a narrow, tech-led
As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the undisputed "darling" of the global equity markets, propelled by the unprecedented success of its GLP-1 (glucagon-like peptide-1) agonists, Ozempic and Wegovy. However, the early months [...]
Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
